Search clinical trials for: recurrent endometrial cancer

Total 90542 results

GOG Foundation
Novartis Pharmaceuticals

Active, not recruiting

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Advanced, Persistent, or Recurrent Endometrial Cancer

United States
University of Colorado, Denver
National Cancer Institute (NCI); Clovis Oncology, Inc.

Active, not recruiting

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Metastatic Endometrial Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Recurrent Ovarian Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Uterine Corpus Cancer | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy
EQRx International, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Withdrawn

Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Endometrial Carcinoma

United States
M.D. Anderson Cancer Center

Completed

RAD001 in Recurrent Endometrial Cancer Patients

Endometrial Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
ARCAGY/ GINECO GROUP

Completed

GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer (ENDOPIK)

Endometrial Cancer

France
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC

Completed

Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma (ENDOVIE)

Metastatic Cancer | Endometrial Cancer | Advanced Cancer | Oncology | Recurrent Cancer

France
Medical College of Wisconsin
Genentech, Inc.; Clovis Oncology, Inc.

Completed

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR)

Uterine Carcinosarcoma | Endometrial Cancer

United States
University of Chicago

Suspended

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Brenner Tumor | Malignant Ascites | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer and other conditions

United States
NCIC Clinical Trials Group
Ariad Pharmaceuticals

Completed

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Endometrial Cancer

Canada
NCIC Clinical Trials Group
National Cancer Institute (NCI)

Completed

Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma

Sarcoma | Endometrial Cancer

Canada
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
Dana-Farber Cancer Institute
AstraZeneca

Terminated

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Recurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...

United States
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma (P204)

Ovarian Cancer | Carcinosarcoma | Endometrial Cancer | Uterine Cancer

United States
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Active, not recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

Ovarian Carcinosarcoma | Endometrial Carcinosarcoma

France
Ohio State University Comprehensive Cancer Center
ImmunoGen, Inc.; Clovis Oncology, Inc.

Active, not recruiting

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Folate Receptor Alpha Positive | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Uterine Serous Carcinoma | Recurrent Uterine Carcinosarcoma | Platinum...

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Cancer
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Donna Hammond, PhD
National Cancer Institute (NCI); ChromaDex, Inc.

Terminated

NR in Chemo-induced Peripheral Neuropathy

Breast Cancer Metastatic | Chemotherapy-induced Peripheral Neuropathy | Head and Neck Cancer Stage IV | Endometrial Cancer Stage IV | Platinum-resistant Recurrent Ovarian Cancer

United States
Cancer Trials Ireland

Terminated

Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06

Endometrial Cancer | Radiation Toxicity | Gastrointestinal Complications | Urinary Complications

Ireland
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell... and other conditions

United States, Canada
National Cancer Institute, Naples

Active, not recruiting

Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer (MITO END-3)

Endometrial Cancer

Italy
WellSpan Health

Active, not recruiting

Endometrial Cancer Recurrence in Patients Taking Metformin

Recurrent Endometrial Carcinoma

United States
Haider Mahdi
Mirati Therapeutics Inc.

Withdrawn

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Solid Tumors | Recurrent Endometrial Cancer

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company

Completed

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Endometrial Cancer | Recurrent Endometrial Cancer

United States
Chimerix

Active, not recruiting

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Endometrial Cancer Recurrent

United States
Floor Backes

Terminated

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Lynch Syndrome | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Mismatch Repair Deficiency | Recurrent Uterine Corpus Carcinosarcoma

United States
Floor Backes
Eisai Inc.

Completed

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Fallopian Tube Carcinoma | Recurrent Endometrial Cancer | Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Withdrawn

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Recurrent Endometrial Cancer | Recurrent Ovarian Cancer
Xenetic Biosciences, Inc.

Terminated

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Endometrial Cancer

United States
Vanderbilt-Ingram Cancer Center
AstraZeneca; Syndax Pharmaceuticals

Terminated

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Recurrent Endometrial Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Primary Peritoneal... and other conditions

United States
Imperial College London
North Eastern German Society of Gynaecological Oncology; Takeda Pharmaceuticals...

Active, not recruiting

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (DICE)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma

United Kingdom, Germany
MacroGenics

Completed

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Completed

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
Hospices Civils de Lyon

Completed

Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients (ENDOLA)

Recurrent Endometrial Cancer

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Estrogen Receptor Positive | Postmenopausal

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7

United States, Canada, Japan
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Vall d'Hebron Institute of Oncology

Completed

Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)

Endometrial Neoplasms

Spain
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer... and other conditions

United States
University College, London
Medivation, Inc.

Withdrawn

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer (PANDA)

Endometrial Cancer

United Kingdom
Pamela Munster
Pfizer; Xynomic Pharmaceuticals, Inc.

Withdrawn

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

Search clinical trials for: recurrent endometrial cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations